Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.
Saved in:
| Title: | Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. |
|---|---|
| Authors: | Andrews DM; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia. daniel.andrews@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. daniel.andrews@petermac.org., Sullivan LC; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia., Baschuk N; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Chan CJ; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.; Department of Pathology and Immunology, Monash University, Prahran, Australia., Berry R; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Australia., Cotterell CL; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Lin J; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia., Halse H; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Watt SV; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia., Poursine-Laurent J; Rheumatology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., Wang CR; Department of Microbiology and Immunology, Northwestern University, Chicago, Illinois, USA., Scalzo AA; Centre for Ophthalmology and Vision Science, University of Western Australia, Crawley, Australia.; Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Australia., Yokoyama WM; Rheumatology Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.; Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri, USA., Rossjohn J; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Australia., Brooks AG; Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia., Smyth MJ; Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia. mark.smyth@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. mark.smyth@petermac.org.; Department of Pathology and Immunology, Monash University, Prahran, Australia. mark.smyth@petermac.org. |
| Source: | Nature immunology [Nat Immunol] 2026 Aug; Vol. 27 (8), pp. 1764. |
| Publication Type: | Expression of Concern |
| Journal Info: | Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
